The majority of cancer drugs approved in Europe between 2009 and 2013 entered the market without clear evidence that they improved survival or quality of life for patients, finds a study published by The BMJ today.

Even where drugs did show survival gains over existing treatments, these were often marginal.

To discuss that, we're joined by Huseyin Naci, assistant professor of health policy at the London School of Economics.